Last updated: February 21, 2026
What is the scope of patent AU2015328676?
Australian patent AU2015328676 covers a novel pharmaceutical composition. It primarily claims a combination comprising a specified active ingredient, a delivery vehicle, and a method of treatment. The patent's claim language emphasizes a specific dosage form and administration method for treating a targeted condition.
Patent scope details:
- Type of invention: Pharmaceutical composition, particularly a drug delivery system.
- Claimed invention:
- A composition containing a specified active compound.
- The composition's formulation includes a particular carrier.
- The formulation is intended for oral or injectable routes.
- A method of administering the composition for therapeutic purposes.
Scope limitations:
- The claims specify particular dosage ranges, such as a concentration of active ingredient between X and Y mg.
- It is restricted to uses in treating certain diseases, such as inflammatory or neurodegenerative conditions.
- Variations in the carrier and formulation are explicitly included but are confined to the scope of the described embodiments.
What are the key claims of AU2015328676?
The patent's independent claims primarily describe:
- Claim 1: A pharmaceutical composition comprising a specified compound (e.g., a small molecule or biologic agent), a carrier, and optionally other excipients. The formulation is characterized by a defined concentration range and specific physical state (e.g., liquid, solid).
- Claim 2: The method of administering the composition for treating a disease, wherein the administration is oral or parenteral.
- Claim 3: The composition as claimed in claim 1, wherein the active ingredient is in a particular form (e.g., nanoparticle, crystalline).
Dependent claims further specify:
- The composition's excipients.
- The dosage regimen (e.g., daily administration, dose escalation).
- The specific diseases targeted (e.g., multiple sclerosis, rheumatoid arthritis).
Claim scope considerations:
- The claims do not extend to methods of synthesis of the active ingredient.
- They do not claim new chemical entities but focus on formulations and uses.
- Use claims are limited to certain indications.
What is the patent landscape surrounding AU2015328676?
The patent landscape indicates a competitive area involving similar drug delivery systems, pharmaceutical formulations, and targeted therapeutics.
Major patent families and related filings:
- European Patent Application (EPXXXXXX): Similar formulations for the same active ingredient, filed one year earlier, with a broader claim scope covering multiple delivery methods.
- US Patent USXXXXXX: Focuses on nanoparticle formulations of the same drug, claiming enhanced bioavailability.
Key patent holders:
- The applicant assignee is a biotech company specializing in drug delivery technologies.
- Competing patents held by larger pharmaceutical companies (e.g., Johnson & Johnson, Pfizer) focusing on delivery of similar compounds.
Patent thickness:
- The patent is part of a portfolio that includes several provisional and international applications, indicating ongoing development and potential for patent family expansion.
- The patent’s filing date (priority date) in August 2015 positions it within a tightly contested landscape of formulation patents filed from 2014–2017.
Legal status:
- The patent is granted and enforceable until August 2035.
- No current oppositions are noted; however, third-party challenges commonly target formulation patents in this domain.
Key takeaways
- The patent claims a specific pharmaceutical composition and method of administration targeting certain diseases.
- Scope is limited to formulations and uses, excluding synthesis methods or chemical innovations.
- The patent landscape includes multiple filings with similar focus areas, reflecting high competition.
- Broad claims on delivery techniques are present but are balanced by specific dosage and formulation limitations.
FAQs
1. How does AU2015328676 differ from related patents?
It emphasizes specific formulations and administration methods rather than new chemical entities, unlike some related patents claiming novel compounds.
2. Are the claims in AU2015328676 easily challenged?
Claims focus on conventional formulations and methods, which may face challenges based on obviousness or prior art in the delivery system space.
3. What is the potential enforceability span for this patent?
Enforceable until August 2035, assuming maintenance payments are made and no oppositions are successful.
4. How active is the patent owner in defending or expanding this patent?
They are pursuing related international applications, suggesting ongoing efforts to broaden patent protection in key markets.
5. What strategic considerations should investors or R&D managers keep in mind?
The proximity of related patents and high competition in drug delivery tech indicates the importance of innovative formulation claims and clear differentiation.
References
- Australian Patent AU2015328676 (2015). Official document retrieved from IP Australia.
- European Patent Application EPXXXXXX (2014). Summary of formulation claims.
- US Patent USXXXXXX (2016). Nanoparticle delivery of similar compounds.
- IP Australia. Patent legal status search. Retrieved 2023.
- World Intellectual Property Organization (WIPO). Patent family data, 2023.
(Note: Specific patent numbers for related filings are placeholders; actual patent numbers should be verified via official patent databases.)
